NASDAQ:NKNantkwest Stock Price, Forecast & News

Nantkwest's stock was trading at $3.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NK shares have increased by 198.9% and is now trading at $10.52.
View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Nantkwest.

Nantkwest is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020.
View our earnings forecast for Nantkwest.

Nantkwest Inc (NASDAQ:NK) issued its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.02. The biotechnology company earned $0.02 million during the quarter. Nantkwest had a negative net margin of 112,350.85% and a negative return on equity of 51.94%.
View Nantkwest's earnings history.

1 Wall Street analysts have issued 1-year price objectives for Nantkwest's shares. Their forecasts range from $18.00 to $18.00. On average, they anticipate Nantkwest's share price to reach $18.00 in the next year. This suggests a possible upside of 71.1% from the stock's current price.
View analysts' price targets for Nantkwest.

Media stories about NK stock have been trending very positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nantkwest earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term.
View the latest news about Nantkwest.

Nantkwest saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 4,890,000 shares, a drop of 9.8% from the July 15th total of 5,420,000 shares. Based on an average daily volume of 2,460,000 shares, the days-to-cover ratio is currently 2.0 days. Approximately 14.0% of the shares of the stock are short sold.
View Nantkwest's Current Options Chain.

Some companies that are related to Nantkwest include Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Momenta Pharmaceuticals (MNTA), Ablynx (ABLYF), Denali Therapeutics (DNLI), Sorrento Therapeutics (SRNE), Fate Therapeutics (FATE), Twist Bioscience (TWST), Immunovant (IMVT), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), Mesoblast (MESO), BAVARIAN NORDIC/S (BVNRY), Sangamo Therapeutics (SGMO) and Legend Biotech (PCVX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nantkwest investors own include Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Novavax (NVAX), Mallinckrodt (MNK), Opko Health (OPK), Amicus Therapeutics (FOLD), NovaBay Pharmaceuticals (NBY), Bausch Health Companies (BHC), Fate Therapeutics (FATE) and Immunomedics (IMMU).

(NK) raised $150 million in an initial public offering on Tuesday, July 28th 2015. The company issued 7,000,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager.

Nantkwest trades on the NASDAQ under the ticker symbol "NK."

Nantkwest's stock is owned by a variety of institutional and retail investors. Top institutional investors include Meridian Investment Counsel Inc. (0.10%), Creative Planning (0.06%), New York State Common Retirement Fund (0.03%), Principal Financial Group Inc. (0.02%), UBS Group AG (0.02%) and SG Americas Securities LLC (0.02%). Company insiders that own Nantkwest stock include Barry J Simon, John C Thomas, Patrick Soon-Shiong and Steve Gorlin.
View institutional ownership trends for Nantkwest.

NK stock was acquired by a variety of institutional investors in the last quarter, including Meridian Investment Counsel Inc., New York State Common Retirement Fund, Principal Financial Group Inc., SG Americas Securities LLC, Creative Planning, State Board of Administration of Florida Retirement System, UBS Group AG, and Strs Ohio.
View insider buying and selling activity for Nantkwest.

Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NK stock can currently be purchased for approximately $10.52.

Nantkwest has a market capitalization of $1.04 billion and generates $40,000.00 in revenue each year. The biotechnology company earns $-65,790,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Nantkwest employs 161 workers across the globe.

The official website for Nantkwest is www.nantkwest.com.

Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]